Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Inclusion Criteria: * Serum LDL-C levels\>100 mg/dL at screening visit. * Male or female subject, between 18 and 65 years inclusive. * Body weight between 50.0 and 95.0 kg inclusive if male, between 40.0 kg and 85.0 kg inclusive if female, body mass index (BMI) between 18.0 and 30.0 kg/m² inclusive. * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * Normal vital signs after 10 minutes resting in supine position. * Normal standard 12-lead ECG after 10 minutes resting in supine position. * Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects. * If female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal. Exclusion Criteria: * Subjects indicated for the use of statins according to criteria in National Cholesterol Education Program adult treatment panel III Guidelines, as updated in 2004 (see Appendix C). * Initiation of a new diet or major change to a previous diet within 4 weeks prior to Screening (Day -21 to -2). Subjects must be willing to maintain a consistent diet for the duration of the study. * Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening (Day -21 to -2), including but not limited to statins, ezetimibe, fibrates, niacin, or omega-3 fatty acids, bile acid resins. * Fasting serum triglycerides \>200 mg/dL measured after an 8 to 12 hour fast. * History of a hypersensitivity reaction to doxycycline or similar compound. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.